Press releases & Latest news
Isofol’s drug candidate arfolitixorin receives clinical patent approval in the United States
GOTHENBURG, Sweden, May 21, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a…
Isofol Reports 58 % Overall Response Rate
Isofol Reports 58 % Overall Response Rate in Patients with Metastatic Colorectal Cancer in Phase 1/2a Open Label Extension Study…
Poadcast – “The Cancer Gene”
Listen to recent episode from The Cancer Gene podcast features Anders Rabbe, CEO of Isofol, discussing colorectal cancer and the…
Upcoming Events
- Financial report - Q1 2019
May 23, 2019 - May 23, 2019 - Annual General Meeting 2019
May 23, 2019 - May 23, 2019 - Pre-ASCO seminar, Stockholm
May 28, 2019 - May 28, 2019 - ASCO, Annual Meeting 2019, Chicago
May 31, 2019 - June 04, 2019